MedTrace Logo

Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients

NCT04792021 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-04-27

No results posted yet for this study

Summary

The purpose of the study is to assess the potential therapeutic effect of N-acetylcysteine "NAC" in COVID 19 patients.

Conditions

  • Corona Virus Disease 19 (Covid19)
  • Corona Virus Infection
  • Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV2)

Interventions

DRUG

N-acetylcysteine

Oral formulation: 600 mg sachets of N-acetylcysteine

Sponsors & Collaborators

  • Misr International University

    collaborator OTHER

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Sara M. Sherkawy, B.S.P · Misr International University

  • Lamia El Wakeel, Professor · Ain Shams University

  • Mona Schaalan, Professor · Misr International University

  • Ayman Moharram, Professor · El Kasr El Einy Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-09
Primary Completion
2021-09-13
Completion
2022-04-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04792021 on ClinicalTrials.gov